Dichotomous Role of Interferon-gamma in Allogeneic Bone Marrow Transplant

Overview

Journal Biol Blood Marrow Transplant

Date 2009 Oct 14

PMID 19822293

Citations 35

Authors

Ying Lu

Edmund K Waller

Affiliations

Soon will be listed here.

Abstract

Interferon (IFN)-gamma is a pleiotropic cytokine with a central role in innate and adaptive immunity. As a potent pro-inflammatory and antitumor cytokine, IFN-gamma is conventionally thought to be responsible for driving cellular immune response. On the other hand, accumulating evidence suggests that IFN-gamma also has immunosuppressive activity. An important role for IFN-gamma in inhibiting graft-versus-host disease (GVHD) has been demonstrated in murine models, despite IFN-gamma being one of the key factors amplifying T cell activation during the process of acute GVHD (aGVHD), the major complication and cause of post-transplant mortality in allogeneic bone marrow transplantation (BMT). At the same time, IFN-gamma facilitates graft-versus-leukemia (GVL) activity. Dissociation of GVL effects from GVHD has been the ultimate goal of allogeneic BMT in the treatment of hematologic malignancies. This paradoxic role of IFN-gamma makes modulating its activity a promising strategy to maximize GVL while minimizing GVHD and improve clinical outcomes in BMT. In this review, the effects of IFN-gamma on GVHD and GVL are discussed with consideration of the mechanism of IFN-gamma action.

Citing Articles

AMPK drives both glycolytic and oxidative metabolism in murine and human T cells during graft-versus-host disease.

Ramgopal A, Braverman E, Sun L, Monlish D, Wittmann C, Kemp F Blood Adv. 2024; 8(15):4149-4162.

PMID: 38810258 PMC: 11345362. DOI: 10.1182/bloodadvances.2023010740.

The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy.

Maurer K, Antin J Front Immunol. 2024; 15:1328858.

PMID: 38558819 PMC: 10978651. DOI: 10.3389/fimmu.2024.1328858.

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis.

Socie G, Niederwieser D, von Bubnoff N, Mohty M, Szer J, Or R Blood. 2023; 141(22):2771-2779.

PMID: 36827620 PMC: 10646803. DOI: 10.1182/blood.2022018579.

IFN-γR/STAT1 signaling in recipient hematopoietic antigen-presenting cells suppresses graft-versus-host disease.

Lu C, Ma H, Song L, Wang H, Wang L, Li S J Clin Invest. 2022; 133(3).

PMID: 36445781 PMC: 9888368. DOI: 10.1172/JCI125986.

T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?.

Campe J, Ullrich E Front Immunol. 2022; 12:806529.

PMID: 35069590 PMC: 8766661. DOI: 10.3389/fimmu.2021.806529.

References

Dickinson A, Sviland L, Hamilton P, USHER P, Taylor P, Jackson G . Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 1994; 13(1):65-70. View

Wood K, Sawitzki B . Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol. 2006; 27(4):183-7. DOI: 10.1016/j.it.2006.02.008. View

Hossain M, Roback J, Pollack B, Jaye D, Langston A, Waller E . Chronic GvHD decreases antiviral immune responses in allogeneic BMT. Blood. 2007; 109(10):4548-56. PMC: 1885501. DOI: 10.1182/blood-2006-04-017442. View

Zhang B, Liu R, Shi D, Liu X, Chen Y, Dou X . Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood. 2008; 113(1):46-57. DOI: 10.1182/blood-2008-04-154138. View

Sykes M, Szot G, Nguyen P, Pearson D . Interleukin-12 inhibits murine graft-versus-host disease. Blood. 1995; 86(6):2429-38. View

Yang Y, Sykes M . The role of interleukin-12 in preserving the graft-versus-leukemia effect of allogeneic CD8 T cells independently of GVHD. Leuk Lymphoma. 1999; 33(5-6):409-20. DOI: 10.3109/10428199909058446. View

Jasperson L, Bucher C, Panoskaltsis-Mortari A, Taylor P, Mellor A, Munn D . Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood. 2007; 111(6):3257-65. PMC: 2265461. DOI: 10.1182/blood-2007-06-096081. View

Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts A . Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008; 2(2):141-50. DOI: 10.1016/j.stem.2007.11.014. View

Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E . IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008; 38(6):1745-55. PMC: 3021120. DOI: 10.1002/eji.200738129. View

10.

Ferrara J, Cooke K, Teshima T . The pathophysiology of acute graft-versus-host disease. Int J Hematol. 2003; 78(3):181-7. DOI: 10.1007/BF02983793. View

11.

Ferrara J, Levine J, Reddy P, Holler E . Graft-versus-host disease. Lancet. 2009; 373(9674):1550-61. PMC: 2735047. DOI: 10.1016/S0140-6736(09)60237-3. View

12.

Hossain M, Roback J, Wang F, Waller E . Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. J Immunol. 2008; 180(10):6892-902. DOI: 10.4049/jimmunol.180.10.6892. View

13.

Steckel N, Kuhn U, Beelen D, Elmaagacli A . Indoleamine 2,3-dioxygenase expression in patients with acute graft-versus-host disease after allogeneic stem cell transplantation and in pregnant women: association with the induction of allogeneic immune tolerance?. Scand J Immunol. 2003; 57(2):185-91. DOI: 10.1046/j.1365-3083.2003.01212.x. View

14.

Brok H, Vossen J, Heidt P . Interferon-gamma-mediated prevention of graft-versus-host disease: development of immune competent and allo-tolerant T cells in chimeric mice. Bone Marrow Transplant. 1997; 19(6):601-6. DOI: 10.1038/sj.bmt.1700707. View

15.

Adam C, King S, Allgeier T, Braumuller H, Luking C, Mysliwietz J . DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood. 2005; 106(1):338-44. DOI: 10.1182/blood-2004-09-3775. View

16.

Mohib K, Guan Q, Diao H, Du C, Jevnikar A . Proapoptotic activity of indoleamine 2,3-dioxygenase expressed in renal tubular epithelial cells. Am J Physiol Renal Physiol. 2007; 293(3):F801-12. DOI: 10.1152/ajprenal.00044.2007. View

17.

Berner V, Liu H, Zhou Q, Alderson K, Sun K, Weiss J . IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med. 2007; 13(3):354-60. DOI: 10.1038/nm1554. View

18.

Li J, Waller E . The yin and yang of adaptive immunity in allogeneic hematopoietic cell transplantation: donor antigen-presenting cells can either augment or inhibit donor T cell alloreactivity. Adv Exp Med Biol. 2006; 590:69-87. DOI: 10.1007/978-0-387-34814-8_5. View

19.

Herberman R, Nunn M, HOLDEN H, LAVRIN D . Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer. 1975; 16(2):230-9. DOI: 10.1002/ijc.2910160205. View

20.

Waller E, Rosenthal H, Jones T, Peel J, Lonial S, Langston A . Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood. 2001; 97(10):2948-56. DOI: 10.1182/blood.v97.10.2948. View